{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:47:50Z","timestamp":1791478070513,"version":"4.3.4"},"reference-count":55,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Cancer cachexia (CC) is a prevalent and debilitating syndrome in cancer patients, characterized by severe muscle and weight loss, leading to increased mortality and reduced quality of life. Despite the significant impact, effective treatments are lacking due to an incomplete understanding of its underlying mechanisms. In this study, we aim to develop drugs that ameliorate the inhibition of muscle differentiation induced by CC. We established an advanced, high-content phenotypic screening system using the serum of cancer patients and identified potential compounds. Methods: We used cancer patients\u2019 sera as pathophysiological stimuli in our screening system to evaluate their effects on muscle atrophy and differentiation. Various histone deacetylase (HDAC) inhibitors were tested for their efficacy. The system\u2019s translational relevance was validated by comparing results with clinical data and in vivo cachexia models. Results: Using our screening system, we evaluated several cancer patients\u2019 sera and found that they reflect clinical features of cancer cachexia. In addition, HDAC inhibitors, particularly those with broad-spectrum inhibition, showed promise as agents to ameliorate the inhibition of muscle differentiation induced by CC sera. This system\u2019s findings were consistent with clinical and in vivo data, highlighting its potential for identifying new drugs. Conclusions: The high-content phenotypic screening system effectively mimics some key aspects of CC pathophysiology on skeletal muscle, providing a valuable tool for drug discovery and understanding CC mechanisms. The translational relevance of our system offers a promising avenue for therapeutic advancements in the management of cancer cachexia, with the potential to improve patient outcomes and quality of life.<\/jats:p>","DOI":"10.3390\/ph18040445","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T11:06:48Z","timestamp":1742555208000},"page":"445","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advanced High-Content Phenotypic Screening to Identify Drugs That Ameliorate the Inhibition of Skeletal Muscle Cell Differentiation Induced by Cancer Cachexia Serum"],"prefix":"10.3390","volume":"18","author":[{"given":"Atsushi","family":"Nakane","sequence":"first","affiliation":[{"name":"Sumitomo Pharma Co., Ltd. 1\u201398, Kasugade-naka 3-chome, Konohana-ku, Osaka 554-0022, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Sumitomo Pharma Co., Ltd. 1\u201398, Kasugade-naka 3-chome, Konohana-ku, Osaka 554-0022, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4109-7657","authenticated-orcid":false,"given":"Hidetaka","family":"Nagata","sequence":"additional","affiliation":[{"name":"Sumitomo Pharma Co., Ltd. 1\u201398, Kasugade-naka 3-chome, Konohana-ku, Osaka 554-0022, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and Classification of Cancer Cachexia: An International Consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41574-018-0123-0","article-title":"Inter-Tissue Communication in Cancer Cachexia","volume":"15","author":"Stemmler","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.smhs.2020.10.003","article-title":"Development and Progression of Cancer Cachexia: Perspectives from Bench to Bedside","volume":"2","author":"Lim","year":"2020","journal-title":"Sports Med. Health Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-Associated Cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Mueller, T.C., Bachmann, J., Prokopchuk, O., Friess, H., and Martignoni, M.E. (2016). Molecular Pathways Leading to Loss of Skeletal Muscle Mass in Cancer Cachexia\u2014Can Findings from Animal Models Be Translated to Humans?. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2121-8"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/cncr.22944","article-title":"A Placebo-controlled Double Blind Trial of Etanercept for the Cancer Anorexia\/Weight Loss Syndrome: Results from N00C1 from the North Central Cancer Treatment Group","volume":"110","author":"Jatoi","year":"2007","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.lungcan.2009.06.020","article-title":"A Placebo-Controlled, Double-Blind Trial of Infliximab for Cancer-Associated Weight Loss in Elderly and\/or Poor Performance Non-Small Cell Lung Cancer Patients (N01C9)","volume":"68","author":"Jatoi","year":"2010","journal-title":"Lung Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"111947","DOI":"10.1016\/j.celrep.2022.111947","article-title":"GDF15 Neutralization Restores Muscle Function and Physical Performance in a Mouse Model of Cancer Cachexia","volume":"42","author":"Song","year":"2023","journal-title":"Cell Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"djv274","DOI":"10.1093\/jnci\/djv274","article-title":"Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia","volume":"107","author":"Tseng","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/jcsm.13073","article-title":"Molecular Mechanisms of Cancer Cachexia-related Loss of Skeletal Muscle Mass: Data Analysis from Preclinical and Clinical Studies","volume":"14","author":"Martin","year":"2023","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mirzoev, T.M. (2020). Skeletal Muscle Recovery from Disuse Atrophy: Protein Turnover Signaling and Strategies for Accelerating Muscle Regrowth. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21217940"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Siddiqui, J.A., Pothuraju, R., Jain, M., Batra, S.K., and Nasser, M.W. (2020). Advances in Cancer Cachexia: Intersection between Affected Organs, Mediators, and Pharmacological Interventions. Biochim. Biophys. Acta (BBA)\u2014Rev. Cancer, 1873.","DOI":"10.1016\/j.bbcan.2020.188359"},{"key":"ref_13","first-page":"e26798","article-title":"What Role Do Inflammatory Cytokines Play in Cancer Cachexia?","volume":"14","author":"Malla","year":"2022","journal-title":"Cureus"},{"key":"ref_14","first-page":"779","article-title":"Muscle Regeneration: Cellular and Molecular Events","volume":"23","author":"Karalaki","year":"2009","journal-title":"In Vivo"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/jcsm.12348","article-title":"Cancer Cachexia Impairs Neural Respiratory Drive in Hypoxia but Not Hypercapnia","volume":"10","author":"Fields","year":"2019","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Inaba, S., Hinohara, A., Tachibana, M., Tsujikawa, K., and Fukada, S. (2018). Muscle Regeneration Is Disrupted by Cancer Cachexia without Loss of Muscle Stem Cell Potential. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205467"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1126\/science.289.5488.2363","article-title":"NF-\u03baB-Induced Loss of MyoD Messenger RNA: Possible Role in Muscle Decay and Cachexia","volume":"289","author":"Guttridge","year":"2000","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Fabio, P., Domiziana, C., Alessandro, F., Gabriella, B., Francesco, M.B., and Paola, C. (2010). Muscle Wasting and Impaired Myogenesis in Tumor Bearing Mice Are Prevented by ERK Inhibition. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013604"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Panguluri, S.K., Bhatnagar, S., Kumar, A., McCarthy, J.J., Srivastava, A.K., Cooper, N.G., Lundy, R.F., and Kumar, A. (2010). Genomic Profiling of Messenger RNAs and MicroRNAs Reveals Potential Mechanisms of TWEAK-Induced Skeletal Muscle Wasting in Mice. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0008760"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.bbrc.2014.03.084","article-title":"The TWEAK\u2013Fn14 Dyad Is Involved in Age-Associated Pathological Changes in Skeletal Muscle","volume":"446","author":"Tajrishi","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jcsm.12678","article-title":"Phenotypic Features of Cancer Cachexia-related Loss of Skeletal Muscle Mass and Function: Lessons from Human and Animal Studies","volume":"12","author":"Martin","year":"2021","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.1152\/ajpendo.00310.2019","article-title":"Effects of Conditioned Media from Murine Lung Cancer Cells and Human Tumor Cells on Cultured Myotubes","volume":"318","author":"Guigni","year":"2020","journal-title":"Am. J. Physiol.-Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/jcb.21833","article-title":"Dexamethasone and Corticosterone Induce Similar, but Not Identical, Muscle Wasting Responses in Cultured L6 and C2C12 Myotubes","volume":"105","author":"Menconi","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"43442","DOI":"10.18632\/oncotarget.9779","article-title":"Chemotherapy-Related Cachexia Is Associated with Mitochondrial Depletion and the Activation of ERK1\/2 and P38 MAPKs","volume":"7","author":"Barreto","year":"2016","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jcsm.12885","article-title":"Ovarian Cancer Ascites Induces Skeletal Muscle Wasting in Vitro and Reflects Sarcopenia in Patients","volume":"13","author":"Ubachs","year":"2022","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s11626-013-9655-8","article-title":"Characterization of Primary Human Skeletal Muscle Cells from Multiple Commercial Sources. In Vitro Cell","volume":"49","author":"Owens","year":"2013","journal-title":"Dev.Biol.-Anim."},{"key":"ref_27","first-page":"2295","article-title":"Tumor Necrosis Factor Inhibits Human Myogenesis In Vitro","volume":"8","author":"Miller","year":"1988","journal-title":"Mol. Cell. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"10327","DOI":"10.1074\/jbc.M511131200","article-title":"Tumor Necrosis Factor-like Weak Inducer of Apoptosis Inhibits Skeletal Myogenesis through Sustained Activation of Nuclear Factor-\u03baB and Degradation of MyoD Protein","volume":"281","author":"Dogra","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1096\/fj.06-7537com","article-title":"TNF-related Weak Inducer of Apoptosis (TWEAK) Is a Potent Skeletal Muscle-wasting Cytokine","volume":"21","author":"Dogra","year":"2007","journal-title":"FASEB J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1177\/2472555220942764","article-title":"Z\u2019 Does Not Need to Be > 0.5","volume":"25","author":"Bar","year":"2020","journal-title":"SLAS Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1158\/1535-7163.MCT-09-0689","article-title":"SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer","volume":"9","author":"Sangthongpitag","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1158\/1535-7163.MCT-07-2347","article-title":"KD5170, a Novel Mercaptoketone-Based Histone Deacetylase Inhibitor That Exhibits Broad Spectrum Antitumor Activity in Vitro and in Vivo","volume":"7","author":"Hassig","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1021\/jm8002894","article-title":"Use of the Nitrile Oxide Cycloaddition (NOC) Reaction for Molecular Probe Generation: A New Class of Enzyme Selective Histone Deacetylase Inhibitors (HDACIs) Showing Picomolar Activity at HDAC6","volume":"51","author":"Kozikowski","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"35402","DOI":"10.1074\/jbc.M807045200","article-title":"Pimelic Diphenylamide 106 Is a Slow, Tight-Binding Inhibitor of Class I Histone Deacetylases","volume":"283","author":"Chou","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2008.9","article-title":"A Novel Histone Deacetylase 8 (HDAC8)-Specific Inhibitor PCI-34051 Induces Apoptosis in T-Cell Lymphomas","volume":"22","author":"Balasubramanian","year":"2008","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Tseng, Y.-C., Liva, S.G., Dauki, A.M., Sovic, M., Henderson, S.E., Kuo, Y.-C., Benedict, J.A., Kulp, S.K., Campbell, M., and Bekaii-Saab, T. (2017). Overcoming Resistance to Anabolic Selective Androgen Receptor Modulator (SARM) Therapy in Experimental Cancer Cachexia with Histone Deacetylase Inhibitor AR-42. bioRxiv.","DOI":"10.1101\/214155"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1021\/jm901358y","article-title":"Modified Cap Group Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitor Derivatives Reveal Improved Selective Antileukemic Activity","volume":"53","author":"Fabre","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"C615","DOI":"10.1152\/ajpcell.00540.2019","article-title":"Comparative Profiling of Skeletal Muscle Models Reveals Heterogeneity of Transcriptome and Metabolism","volume":"318","author":"Abdelmoez","year":"2020","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e389942","DOI":"10.1200\/EDBK_389942","article-title":"Current Therapeutic Targets in Cancer Cachexia: A Pathophysiologic Approach","volume":"43","author":"Kadakia","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Neshan, M., Tsilimigras, D.I., Han, X., Zhu, H., and Pawlik, T.M. (2024). Molecular Mechanisms of Cachexia: A Review. Cells, 13.","DOI":"10.3390\/cells13030252"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Cao, Z., Zhao, K., Jose, I., Hoogenraad, N.J., and Osellame, L.D. (2021). Biomarkers for Cancer Cachexia: A Mini Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094501"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.trecan.2019.07.010","article-title":"Impaired Muscle Regeneration in Cancer-Associated Cachexia","volume":"5","author":"Arneson","year":"2019","journal-title":"Trends Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1172\/JCI68523","article-title":"NF-kB-Mediated Pax7 Dysregulation in the Muscle Microenvironment Promotes Cancer Cachexia","volume":"123","author":"He","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Nishima, S., Kashiwada, T., Saito, Y., Yuge, S., Ishii, T., Matsuda, K., Kamio, K., Seike, M., Fukuhara, S., and Gemma, A. (2024). Bortezomib Induces Rho-Dependent Hyperpermeability of Endothelial Cells Synergistically with Inflammatory Mediators. BMC Pulm. Med., 24.","DOI":"10.1186\/s12890-024-03387-x"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"30287","DOI":"10.1074\/jbc.273.46.30287","article-title":"RhoA Signaling via Serum Response Factor Plays an Obligatory Role in Myogenic Differentiation","volume":"273","author":"Wei","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Nevi, L., P\u00f6ll\u00e4nen, N., Penna, F., and Caretti, G. (2023). Targeting Epigenetic Regulators with HDAC and BET Inhibitors to Modulate Muscle Wasting. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216404"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13395-021-00273-6","article-title":"The Pan HDAC Inhibitor Givinostat Improves Muscle Function and Histological Parameters in Two Duchenne Muscular Dystrophy Murine Models Expressing Different Haplotypes of the LTBP4 Gene","volume":"11","author":"Licandro","year":"2021","journal-title":"Skelet. Muscle"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and Efficacy of Givinostat in Boys with Duchenne Muscular Dystrophy (EPIDYS): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7757","DOI":"10.1073\/pnas.112218599","article-title":"Stage-Specific Modulation of Skeletal Myogenesis by Inhibitors of Nuclear Deacetylases","volume":"99","author":"Iezzi","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.cellbio.14.1.167","article-title":"Transcriptional control of muscle development by Myocyte Enhancer FACTOR-2 (MEF2) Proteins","volume":"14","author":"Black","year":"1998","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1093\/emboj\/18.18.5099","article-title":"HDAC4 Deacetylase Associates with and Represses the MEF2 Transcription Factor","volume":"18","author":"Miska","year":"1999","journal-title":"EMBO J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1074\/jbc.M114.600916","article-title":"Histone Deacetylase 6 Is a FoxO Transcription Factor-Dependent Effector in Skeletal Muscle Atrophy","volume":"290","author":"Ratti","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1006\/viro.2002.1690","article-title":"Neuroprotective Effects of IGF-I against TNF\u03b1-Induced Neuronal Damage in HIV-Associated Dementia","volume":"305","author":"Peruzzi","year":"2003","journal-title":"Virology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/labinvest.2009.1","article-title":"Human Peritoneal Fibroblasts Are a Potent Source of Neutrophil-Targeting Cytokines: A Key Role of IL-1\u03b2 Stimulation","volume":"89","author":"Witowski","year":"2009","journal-title":"Lab. Investig."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/4\/445\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:58:07Z","timestamp":1760029087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/4\/445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["ph18040445"],"URL":"https:\/\/doi.org\/10.3390\/ph18040445","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]}}}